ACP-204 for Alzheimer's with psychosis
Treatments studied
Part of Brain & nervous system clinical trials.
This study tests a new medicine called ACP-204 for people with Alzheimer's disease who also have psychosis (like seeing or hearing things that aren't real). It aims to see if the drug can help reduce these symptoms safely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 55 and 95 years old.
- You have been diagnosed with Alzheimer's disease (possible or probable).
- You have experienced psychosis (seeing/hearing things that aren't there or strong false beliefs) for at least 2 months, and this is due to your dementia.
- You have a caregiver or family member who can go with you to all study visits.
- You live in a stable place (home or facility) and do not plan to move.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a long-term medicine (ACP-204) for people with Alzheimer's disease who also have psychosis (hallucinations or delusions). If you took part in the earlier ACP-204 study, this open-label extension lets you continue receiving the medicine to see how well it works over time.
This trial tests a study drug called ML-007C-MA to see if it can safely reduce hallucinations and delusions in people with Alzheimer's disease who also have psychosis. If you or your loved one has Alzheimer's and has been experiencing false beliefs or seeing/hearing things that aren't there for at least two months, this study may be an option.
This Phase 1/2 study tests an Alzheimer’s treatment called ACI-24.060 to see if it affects the disease in people with early Alzheimer’s changes. It includes two groups: older adults with early symptoms and people with Down syndrome who also show Alzheimer’s-related changes on brain scans.
This clinical trial tests an investigational oral medication called KarXT for treating psychosis (hallucinations or delusions) in people with Alzheimer's disease. The study aims to see if the drug can safely reduce these symptoms.
This trial tests a new drug called ACP-204 for people with dementia from Lewy body disease or Parkinson's who also have hallucinations or delusions. The goal is to see if the drug can safely reduce these symptoms without worsening thinking problems.
This study tests a medication called ACP-204 for psychosis (hallucinations or delusions) in people with Lewy body dementia. It is a long-term extension open to patients who completed a previous ACP-204 study, to see if the drug continues to be helpful and safe.
Hear when a new Alzheimer's Disease Psychosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.